$1,000 Genome Latest in Sequencing Scrum: Bentley Joins Solexa | GenomeWeb

After 12 years at the Wellcome Trust Sanger Institute, David Bentley has headed to Solexa as the sequencing company’s chief scientist. “The Solexa technology is coming of age,” Bentley says, and the move reflects his belief that the time is ripe for significant investment in genomic applications. Solexa, a player in the $1,000 genome competition, has a DNA sequencing system in alpha production and expects it to hit the market later this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.